This is a preview of subscription content, log in via an institution to check access.
Notes
The IPF-PRO Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc.
Reference
Fan Y, et al. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest : 29 Jan 2020. Available from: URL: http://doi.org/10.1016/j.chest.2019.12.041
Rights and permissions
About this article
Cite this article
Idiopathic pulmonary fibrosis: cost of hospital care substantial in the US. PharmacoEcon Outcomes News 847, 13 (2020). https://doi.org/10.1007/s40274-020-6589-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6589-8